BIOMAT Database Logo BIOMAT Database Logo

Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. 1993

P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, (Qc), Canada.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008124 Locomotion Movement or the ability to move from one place or another. It can refer to humans, vertebrate or invertebrate animals, and microorganisms. Locomotor Activity,Activities, Locomotor,Activity, Locomotor,Locomotor Activities
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D011597 Psychomotor Performance The coordination of a sensory or ideational (cognitive) process and a motor activity. Perceptual Motor Performance,Sensory Motor Performance,Visual Motor Coordination,Coordination, Visual Motor,Coordinations, Visual Motor,Motor Coordination, Visual,Motor Coordinations, Visual,Motor Performance, Perceptual,Motor Performance, Sensory,Motor Performances, Perceptual,Motor Performances, Sensory,Perceptual Motor Performances,Performance, Perceptual Motor,Performance, Psychomotor,Performance, Sensory Motor,Performances, Perceptual Motor,Performances, Psychomotor,Performances, Sensory Motor,Psychomotor Performances,Sensory Motor Performances,Visual Motor Coordinations
D001931 Brain Mapping Imaging techniques used to colocalize sites of brain functions or physiological activity with brain structures. Brain Electrical Activity Mapping,Functional Cerebral Localization,Topographic Brain Mapping,Brain Mapping, Topographic,Functional Cerebral Localizations,Mapping, Brain,Mapping, Topographic Brain
D002230 Carbidopa An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. Methyldopahydrazine,Carbidopa, (R)-Isomer,Carbidopa, (S)-Isomer,Lodosin,Lodosyn,MK-485,MK-486,MK 485,MK 486,MK485,MK486
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug

Related Publications

P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys.
January 1992, Psychopharmacology,
P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
January 1997, European neurology,
P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys.
January 1996, Advances in neurology,
P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
March 1994, European journal of pharmacology,
P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans.
September 1987, Pharmacology & toxicology,
P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
April 2000, Experimental neurology,
P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Observational studies of dopamine D1 and D2 agonists in squirrel monkeys.
September 1994, Psychopharmacology,
P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.
May 1992, Annals of neurology,
P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
June 1993, The Journal of pharmacology and experimental therapeutics,
P J Bédard, and B Gomez-Mancilla, and P Blanchette, and C Gagnon, and P Falardeau, and T DiPaolo
Effects of D1 and D2 agonists on spontaneous motor activity in MPTP treated mice.
July 1994, Pharmacology & toxicology,
Copied contents to your clipboard!